叶酸代谢通路基因遗传变异预测皮肤黑色素瘤特异性生存
该研究基于两个GWAS数据集(858例和409例皮肤黑色素瘤患者),评估叶酸代谢通路基因的2645个常见SNP与皮肤黑色素瘤特异性生存(CMSS)的关联。基因型-表型相关性分析支持这两个变异通过影响mRNA表达水平参与肿瘤进展。
要点
- MTHFD1 rs1950902和ALPL rs10917006与CMSS独立相关。
- 变异可能通过影响mRNA表达水平影响肿瘤进展。
核心结论
- MTHFD1 rs1950902和ALPL rs10917006可能独立或联合与CMSS相关,未来或可辅助个体化治疗,但需进一步验证。
研究设计与样本
- 研究基于已发表的GWAS数据,发现集包含MD Anderson癌症中心858例患者,验证集包含Nurses' Health Study和Health Professionals Follow-up Study的409例患者。
- 共评估叶酸代谢通路基因中2645个常见SNP(422个基因分型,2223个填充)。
主要发现
- 在两个数据集中均发现MTHFD1 rs1950902 G>A和ALPL rs10917006 C>T与CMSS相关。
- 基因型-表型相关性分析提示SNP相关的mRNA表达水平变化可能是观察到的关联机制。
临床怎么用
- 这两个SNP可能有助于构建CMSS风险预测模型,但需在更大规模研究中验证后方可用于个体化管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Folate metabolism plays an important role in DNA methylation and nucleic acid synthesis and thus may function as a regulatory factor in cancer development. Genome-wide association studies (GWASs) have identified some single-nucleotide polymorphisms (SNPs) associated with cutaneous melanoma-specific survival (CMSS), but no SNPs were found in genes involved in the folate metabolic pathway. OBJECTIVES: To examine associations between SNPs in folate metabolic pathway genes and CMSS. METHODS: We comprehensively evaluated 2645 (422 genotyped and 2223 imputed) common SNPs in folate metabolic pathway genes from a published GWAS of 858 patients from The University of Texas MD Anderson Cancer Center and performed the validation in another GWAS of 409 patients from the Nurses' Health Study and Health Professionals Follow-up Study, in which 95/858 (11·1%) and 48/409 (11·7%) patients died of cutaneous melanoma, respectively. RESULTS: We identified two independent SNPs (MTHFD1 rs1950902 G>A and ALPL rs10917006 C>T) to be associated with CMSS in both datasets, and their meta-analysis yielded an allelic hazards ratio of 1·75 (95% confidence interval 1·32-2·32, P = 9·96 × 10-5 ) and 2·05 (1·39-3·01, P = 2·84 × 10-4 ), respectively. The genotype-phenotype correlation analyses provided additional support for the biological plausibility of these two variants' roles in tumour progression, suggesting that variation in SNP-related mRNA expression levels is likely to be the mechanism underlying the observed associations with CMSS. CONCLUSIONS: Two possibly functional genetic variants, MTHFD1 rs1950902 and ALPL rs10917006, were likely to be independently or jointly associated with CMSS, which may add to personalized treatment in the future, once further validated. What is already known about this topic? Existing data show that survival rates vary among patients with melanoma with similar clinical characteristics; therefore, it is necessary to identify additional complementary biomarkers for melanoma-specific prognosis. A hypothesis-driven approach, by pooling the effects of single-nucleotide polymorphisms (SNPs) in a specific biological pathway as genetic risk scores, may provide a prognostic utility, and genetic variants of genes in folate metabolism have been reported to be associated with cancer risk. What does this study add? Two genetic variants in the folate metabolic pathway genes, MTHFD1 rs1950902 and ALPL rs10917006, are significantly associated with cutaneous melanoma-specific survival (CMSS). What is the translational message? The identification of genetic variants will make a risk-prediction model possible for CMSS. The SNPs in the folate metabolic pathway genes, once validated in larger studies, may be useful in the personalized management and treatment of patients with cutaneous melanoma.
引用
- Dai W, Liu H, Liu Y, et al. Genetic variants in the folate metabolic pathway genes predict cutaneous melanoma-specific survival. Br J Dermatol. 2020. PMID: 31955403. doi:10.1111/bjd.18878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。